06086.HK
Fangzhou Inc.
HKSE · Consumer Cyclical · Drug Manufacturers - General · CN
HKD 0.72
+2.86%Year over year
Reported trailing growth
- Revenue
- +34.1%
- EBITDA
- -1.4%
- EBIT
- +170.7%
- EPS
- +132.8%
- Free cash flow
- +54.9%
- Operating cash flow
- +45.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +17.0%
- EBITDA
- +102.2%
- EBIT
- +101.7%
- Net income
- +101.4%
- EPS
- +101.0%
- Free cash flow
- +98.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026